Axios Pro · Jun 2025
Reports the Series A and frames the company’s fruit-fly platform as a more sustainable alternative to traditional recombinant protein manufacturing.
We make unmakeable proteins with radical advanced biomanufacturing.
Company research
Public company, workplace, funding, and market signals
Updated Aug 16, 2026
Overview
Future Fields is a biotechnology research company that develops a biomanufacturing platform called the EntoEngine™, which uses whole fruit flies (Drosophila) to produce recombinant proteins. The company positions this as a lower-cost, lower-carbon alternative to traditional bioreactors and sells custom protein production services and related bioproducts.
Primary product
EntoEngine™ biomanufacturing platform and custom recombinant protein production services
Founded
2018
Headquarters
Edmonton, Alberta, Canada
Team size
11-50 employees
Industry
Biotechnology Research
Sub-industry
Synthetic biology / biomanufacturing / recombinant protein production
Offices
Edmonton, Alberta, Canada
United States (presence reported)
Business model
B2B services
biomanufacturing/CDMO-like services
product sales
Funding
Stage
Series A
Total raised
$26.9M
Latest round
Series A · Jun 2025
Latest amount
$8M
Jun 2025 · Amplify Capital, BDC Climate Tech Fund, and R7 Partners
Grant
Feb 2023 · Sustainable Development Technology Canada
Seed Round
Apr 2022
Pre Seed Round
Aug 2020 · Y Combinator
People & investors
Leadership
Matt Anderson-Baron
Chief Executive Officer
Laine Lysyk
Protein Biochemistry Lead
Erik Luber
Vice President of Technology
Brandon Kwong
Head of Operations
Diane Jeon
Marketing Lead
Jan Grijpstra
R&D Team Lead Protein Biochemistry
Nagalakshmi Kannuchamy
Regulatory and Quality Assurance Lead
Matthew Alexander
Vice President Finance and Admin
Ela Dudek
VP of Research and Development
Chris Fetterly
Vice President of Sales & Marketing
Founders
Co-founder & COO
Investors
AgFunder
Amplify Capital
Bee Partners
BoxOne Ventures
Builders VC
Business Development Bank of Canada (BDC) Climate Tech Fund
Climate Capital
Green Circle Foodtech Ventures
Grow Agrifood Tech Accelerator
GROW Agrifoodtech Accelerator
Milad Alucozai
Narrative Fund
Pioneer Fund
R7 Partners
Siddhi Capital
Sustainable Development Technology Canada
Toyota Ventures
TRAC VC
University of Alberta Innovation Fund
Y Combinator
Work & culture
Public messaging emphasizes sustainability, ethical production, and economic efficiency. The company highlights a green-certified lab, 1% for the Planet membership, and UN Global Compact participation. Recent hiring posts suggest a growth-oriented, mission-driven culture.
Product & market
Pricing
Custom protein production services; direct pricing not publicly stated
Differentiators
- —First synthetic biology system to use whole fruit flies for recombinant protein production
- —Positioned for difficult proteins and low-cost, low-carbon manufacturing
- —Custom protein service tailored to small and mid-sized biopharma
- —Instar 1.0 biofactory cited as 30x output of conventional protein technology
Technology
EntoEngine™
Instar biofactory
My Green Lab certification
1% for the Planet membership
United Nations Global Compact membership
LinkedIn
GitHub
Google Analytics
WordPress
Customers
Agriculture companies
Food companies
Biopharma companies
Small-to-medium-sized biopharma companies
Biomedical research customers
Competitors
Traditional mammalian cell culture biomanufacturing providers
Yeast-based recombinant protein platforms
Microbial expression systems
Other alternative protein / synthetic biology biomanufacturing startups
Scale & contact
Estimated revenue
$1M-$5M
Estimated monthly visits
4.1K
Traffic estimate as of Jun 2026
Latest news
Future Fields · Jun 2025
Announces an $8M Series A co-led by Amplify Capital, BDC Climate Tech Fund, and R7 Partners to expand commercial traction across agriculture, food, and biopharma markets.
Future Fields · Nov 2024
Launches a 6,000-square-foot downtown Edmonton facility and new service line for custom protein production.
Fierce Pharma · Nov 2024
Covers the launch of Instar 1.0, the company’s 6,000-square-foot Edmonton facility and new service line for exotic tissue-specific proteins.
Future Fields · Sep 2023
Introduces custom protein manufacturing services built on the EntoEngine platform for small and mid-sized biopharma customers.
Jobs and careers at Future Fields
8 jobs at Future Fields
Full-Stack Growth Engineer
Remote
Engineering
Remote
2d ago
Remote
Full-time
Health Coach
Remote
Performance Team
Remote
2w ago
Remote
Full-time
Health Coach Manager
Remote
Performance Team
Remote
2w ago
Remote
Full-time
Lead Android Engineer
Remote
Engineering
Remote
1mo ago
Remote
Full-time
Applied AI Engineer
Remote
Engineering
Remote
3mo ago
Remote
Full-time
Senior Product Designer
Remote
Product
Remote
3mo ago
Remote
Full-time
Staff Product Manager
Remote
Product
Remote
3mo ago
Remote
Full-time
Backend Engineer (Golang)
Remote
Engineering
Remote
6mo ago
Remote
Full-time